Table 1 Ratio of receptor–ligand binding site areas

From: Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab

TNFRSF complex PDB code Receptor chain Ligand chain BSA (Å2) Adjacent ligand chain BSA (Å2) Ratio of site 1 to site 2
4-1BB+4-1BBL   X A 808 C 138 5.86:1
4-1BB+4-1BBL 6MGP Y B 827 A 114 7.25:1
4-1BB+4-1BBL   Z C 833 B 112 7.43:1
CD40+CD154 3QD6 R B 648 C 339 1.91:1
FasL+DcR3 4MSV B A 472 Aa 460 1.02:1
LIGHT+DcR3 4J6G D B 545 Ba 464 1.17:1
TNFα+TNFR2 3ALQ R A 716 B 619 1.16:1
OX40+OX40L 2HEV R Fa 583 F 447 1.30:1
TNFβ+TNFR1 1TNR R A 599 Aa 518 1.16:1
LTβ+LTβR 4MXW R B 490 D 332 1.48:1
  1. a denotes chain generated by symmetry operator